FDA warning against the use of Balguti Kesaria Ayurvedic Medicine due to risk of lead poisoning

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: The U.S. Food and Drug Administration is warning parents and caregivers not to use “Balguti Kesaria (or Kesaria Balguti) Ayurvedic Medicine” due to the risk of lead poisoning.

FDA has not reviewed this product for safety or effectiveness. Exposure to lead can cause serious damage to the central nervous system, the kidneys and the immune system. In children, chronic exposure to lead—even at low levels—is associated with impaired cognitive function, including reduced IQ, behavioral difficulties, and other problems.

BACKGROUND: This product is sold online and manufactured by multiple companies, including Kesari Ayurvedic Pharmacy in India. Individuals have also mailed or brought the product into the United States. “Balguti Kesaria Ayurvedic Medicine” is used with infants and children for a variety of conditions including rickets, cough and cold, worms and dentition (teething).

FDA initially learned of this risk from the North Carolina Division of Public Health after the product was tested and found to contain high levels of lead. FDA was also notified by the Michigan Department of Health and Human S...

Recommended for you

  • MedWatch Drug Updates
  • 1 comment

Recall of Riomet (Metformin Hydrochloride Oral Solution) by Sun Pharmaceutical: Presence of microbial contamination

  • MedWatch Drug Updates
  • 1 comment

Recall of pharmacist choice alcohol prep pads by simple diagnostics due to quality concerns.

  • MedWatch Drug Updates
  • 1 comment

Fading print on label of AlbuRx 25, Albumin (Human) 25% solution

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Biotin (Vitamin B7) interferes with certain lab tests

  • MedWatch Drug Updates
  • 1 comment

FDA investigated life-threatening adverse events associated with Limbrel Capsules by Primus Pharmaceuticals

  • MedWatch Drug Updates
  • 1 comment

Recall of Diphenoxylate Hydrochloride and Atropine Sulfate by Greenstone: Sub-potent or super-potent product

  • MedWatch Drug Updates
  • 1 comment

Recall of Nexterone (amiodarone HCl) 150 mg/100 mL premixed injection by Baxter- Presence of particulate matter

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Increased risk of heart-related death with febuxostat (Uloric)

  • MedWatch Drug Updates
  • 1 comment

FDA update: Type III endoleaks associated with the use of endovascular graft systems

  • MedWatch Drug Updates
  • 1 comment

FDA update: High risk of mortality and neurological adverse events when using SynCardia's TAH-t C2 Driver System

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Bridge Occlusion Balloon Catheter Model 590-001 by Spectranetics: Blocked guidewire lumen

  • MedWatch Drug Updates
  • 1 comment

FDA warns against use of injectable silicone for body contouring and enhancement

  • FDA Drug Updates
  • 1 comment

FDA approved Aliqopa (copanlisib) for the treatment of relapsed follicular lymphoma

  • FDA Drug Updates
  • 1 comment

FDA approved Mvasi (bevacizumab-awwb) for the treatment of cancer

  • MedWatch Drug Updates
  • no comment

FDA safety alert for compounded glutamine, arginine, and carnitine product for injection by United Pharmacy

  • MedWatch Drug Updates
  • no comment

FDA recommends separate dosing for Kayexalate (sodium polystyrene sulfonate) from all other oral drugs

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Intra-Aortic Balloon Pump by Datascope/MAQUET- False blood detection alarm and ingress of fluid into the pump

  • MedWatch Drug Updates
  • 1 comment

Recall of DBA pain relief naturally products by Ridge Properties: Violation of GMP

  • MedWatch Drug Updates
  • 1 comment

Voluntary field action for Infant/Child Reduced Energy Defibrillation Electrodes by Cardinal Health

  • MedWatch Drug Updates
  • 1 comment

Recall of Midazolam injection, USP, 2 mg/2 mL by Fresenius Kabi: contains different drug

  • MedWatch Drug Updates
  • 1 comment

FDA statement on risks of unapproved use of Keytruda (pembrolizumab) for treatment of multiple myeloma

  • MedWatch Drug Updates
  • 1 comment

Recall of Piyanping Anti-Itch Lotion by Lucky Mart Inc.: Contain wrong active pharmaceutical ingredient

  • MedWatch Drug Updates
  • 1 comment

FDA update: Risk of major adverse cardiac events with the use of Absorb GT1 Bioresorbable Vascular Scaffold

  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

  • FDA Drug Updates
  • 1 comment

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

  • MedWatch Drug Updates
  • 1 comment

Voluntary market withdrawal of Octagam 10% immune globulin IV (human) liquid preparation by Octapharma

  • MedWatch Drug Updates
  • 1 comment

Recall of injectable products by SCA Pharmaceuticals: Products may contain microbial contamination

  • MedWatch Drug Updates
  • 1 comment

Class I recall of Penumbra 3D Revascularization device by Penumbra: delivery wire may break or separate during use

  • FDA Drug Updates
  • 1 comment

FDA approved Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for Hepatitis C

  • FDA Drug Updates
  • 1 comment

FDA approved Nerlynx (neratinib) for breast cancer